United States Biotechnology & Medical Research

FibroGen Inc (FGEN)

Track

The most recent insider trading activity occurred on November 17, 2025, with CEO Thane Wettig acquiring 2,700 shares. Prior to this, Wettig made another purchase on November 13, 2025. Earlier transactions in 2025 also show significant buying activity from both Wettig and James A. Schoeneck. The last reported sale was in July 2023.
Stock chart
Ticker: FGEN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Wettig Thane
CEO
1 purchase — total 24,570 USD
Buy 17 Nov 2025
Value US$2,490,824.02 | Price 419.07 | Shares 90,964
Buy 13 Nov 2025
Value US$4,830,116.22 | Price 338.48 | Shares 75,147
Buy 30 Jun 2025
Value US$119,484.69 | Price 5.07 | Shares 23,567
Buy 24 Mar 2025
Value US$50,663.00 | Price 0.35 | Shares 145,000
Buy 21 Mar 2025
Value US$17,040.00 | Price 0.34 | Shares 50,000
Buy 20 Mar 2025
Value US$88,000.00 | Price 0.35 | Shares 250,000
Buy 12 Jun 2024
Value US$25,883.91 | Price 1.17 | Shares 22,123
Buy 7 Mar 2024
Value US$95,470.00 | Price 1.91 | Shares 50,000
Planned sale 1 Sep 2023
Value US$2,060.00 | Price 1.03 | Shares 2,000
Proposed sale 1 Sep 2023
Value US$2,120.00 | Price 1.06 | Shares 2,000
Planned sale 4 Aug 2023
Value US$3,820.00 | Price 1.91 | Shares 2,000
Proposed sale 4 Aug 2023
Value US$3,820.00 | Price 1.91 | Shares 2,000
Planned sale 11 Jul 2023
Value US$5,380.00 | Price 2.69 | Shares 2,000
Proposed sale 11 Jul 2023
Value US$5,460.00 | Price 2.73 | Shares 2,000
Sale 7 Jul 2023
Value US$5,264.00 | Price 2.80 | Shares 1,880
Sale 23 Jun 2023
Value US$13,074.99 | Price 16.53 | Shares 791
Proposed sale 23 Jun 2023
Value US$13,074.96 | Price 16.53 | Shares 791
Planned sale 14 Jun 2023
Value US$17,460.00 | Price 17.46 | Shares 1,000
Planned sale 14 Jun 2023
Value US$87,465.00 | Price 16.66 | Shares 5,250
Planned sale 13 Jun 2023
Value US$110,000.00 | Price 17.60 | Shares 6,250
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-17 2025-11-17 B Purchase
3.6
Wettig Thane

CEO

Executive Director
90,964 -44.1%
419.07
US$2,490,824 		90,964 -44.1% 419.07 US$2,490,824
2025-11-17 2025-11-13 B Purchase
3.6
Wettig Thane

CEO

Executive Director
75,147 -37.7%
338.48
US$4,830,116 		75,147 -37.7% 338.48 US$4,830,116
2025-07-02 2025-06-30 B Purchase
3.1
Schoeneck James A
Non-Executive Director
9,356 -8.1%
349.78
US$1,829,287 		9,356 -8.1% 349.78 US$1,829,287
2025-03-25 2025-03-24 B Purchase
3.6
Wettig Thane

CEO

Executive Director
145,000 +36.4%
0.35
US$50,663 		145,000 +36.4% 0.35 US$50,663
2025-03-24 2025-03-21 B Purchase
3.1
Schoeneck James A
Non-Executive Director
50,000 +15.4%
0.34
US$17,040 		50,000 +15.4% 0.34 US$17,040
2025-03-24 2025-03-20 B Purchase
3.1
Schoeneck James A
Non-Executive Director
250,000 +339.1%
0.35
US$88,000 		250,000 +339.1% 0.35 US$88,000
2024-06-13 2024-06-12 B Purchase
0.5
Adib Deyaa

Chief Medical Officer

Officer
22,123 +36.9%
1.17
US$25,884 		22,123 +36.9% 1.17 US$25,884
2024-03-11 2024-03-07 B Purchase
3.6
Wettig Thane

CEO

Officer
50,000 +11.9%
1.91
US$95,470 		50,000 +11.9% 1.91 US$95,470
2023-09-06 2023-09-01 PlS Planned sale
2.9
Henderson Jeffrey William
Non-Executive Director
2,000 -6.5%
1.03
US$2,060 		2,000 -6.5% 1.03 US$2,060
2023-09-01 2023-09-01 PrS Proposed sale
2.9
Jeffrey Henderson

Director

Non-Executive Director
2,000
1.06
US$2,120 		2,000 1.06 US$2,120
2023-08-08 2023-08-04 PlS Planned sale
2.9
Henderson Jeffrey William
Non-Executive Director
2,000 -6.1%
1.91
US$3,820 		2,000 -6.1% 1.91 US$3,820
2023-08-04 2023-08-04 PrS Proposed sale
2.9
Jeffrey Henderson

Director

Non-Executive Director
2,000
1.91
US$3,820 		2,000 1.91 US$3,820
2023-07-13 2023-07-11 PlS Planned sale
2.9
Henderson Jeffrey William
Non-Executive Director
2,000 -5.7%
2.69
US$5,380 		2,000 -5.7% 2.69 US$5,380
2023-07-11 2023-07-11 PrS Proposed sale
2.9
Jeffrey Henderson

Director

Non-Executive Director
2,000
2.73
US$5,460 		2,000 2.73 US$5,460
2023-07-10 2023-07-07 S Sale
2.8
Conterno Enrique A

Chief Executive Officer

Executive Director
1,880 -0.5%
2.80
US$5,264 		1,880 -0.5% 2.80 US$5,264
2023-06-26 2023-06-23 S Sale
3.6
Wettig Thane

Chief Commercial Officer

Officer
791 -0.7%
16.53
US$13,075 		791 -0.7% 16.53 US$13,075
2023-06-23 2023-06-23 PrS Proposed sale
3.6
Wettig Thane

Officer

Officer
791
16.53
US$13,075 		791 16.53 US$13,075
2023-06-15 2023-06-14 PlS Planned sale
3.9
Chung Christine

SVP, China Operations

Officer
1,000 -0.4%
17.46
US$17,460 		1,000 -0.4% 17.46 US$17,460
2023-06-15 2023-06-14 PlS Planned sale
3.9
Chung Christine

SVP, China Operations

Officer
5,250 -2.2%
16.66
US$87,465 		5,250 -2.2% 16.66 US$87,465
2023-06-15 2023-06-13 PlS Planned sale
3.9
Chung Christine

SVP, China Operations

Officer
6,250 -2.5%
17.60
US$110,000 		6,250 -2.5% 17.60 US$110,000
Explore more

More insider trading research around FibroGen Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America